Urinary pancreatic stone protein (PSP) levels were measured in 68 diabetic patients and 170 healthy controls to investigate the relationship between the progression of diabetic nephropathy and PSP excretion. Urinary albumin, N-acetyl-p-glucosaminidase (NAG), ax-microglobulin, creatinine clearance, and the blood PSP level were also determined in the diabetic patients. The urinary glucose level and glycemic control did not influence the urinary PSP level. In patients with normoalbuminuria (urinary albumin <20 mg/gCr, n=31), microalbuminuria (20-200 mg/Cr, n=19), and macroalbuminuria (>200 mg/gCr, n=18), the mean urinary PSP level was 347, 507, and 860 |0g/gCr, respectively. These levels were significantly higher than the level in normal volunteers (168 |ilg/gCr, p<0.01). A significant positive correlation was observed between the urinary PSP level and the NAGor aj-microglobulin levels (p<0.01). There was a stronger correlation with ocjmicroglobulin. Blood PSP levels were also elevated in patients who had renal impairment with a decreased creatinine clearance. In conclusion, urinary PSP excretion was increased from the initial stage of diabetic nephropathy and this increase became more marked as nephropathy progressed. Increased PSP excretion may reflect renal tubular dysfunction. (Internal Medicine 37: 500-503, 1998) Key words: urinary pancreatic stone protein (PSP), urinary albumin, urinary armicroglobulin, urinary N-acetyl-p-glucosaminidase (NAG)
Introduction
Pancreatic stone protein (PSP) is a substance which inhibits calcium carbonate precipitation in pancreatic fluid ( 1 , 2) . It is a low molecular weight protein (14-19 kd) with five different forms (PSP-S1-5). PSP mRNAis mainly detected in the pancreas, but its expression has also been observed in the gastric mucosa and the kidneys (3) . PSP has been found in the urine and renal calculi of healthy individuals (4), suggesting a physiological role ofPSP in the kidneys. Previously, we reported that PSP forms, S2-5 are present in the urine of normal individuals and that the PSPlevels are correlated with those of N-acetyl-pglucosaminidase (NAG) (5). We also found that urinary PSP was increased markedly in patients with various renal diseases, including diabetic nephropathy. In some of these patients, urinary PSP was present in forms other than PSP-S2-5 (6). In the present study, we determined urinary PSP levels in patents with diabetes to investigate the mechanismof the increase in urinary PSP excretion, and also assessed the changes of urinary PSP excretion which accompanied the progression of nephropathy.
Materials and Methods

Subjects
The diabetic subjects consisted of 68 outpatients attending the diabetic clinic of Ogaki Municipal Hospital. Their ages ranged between 20 and 84 years (mean: 61 years), and there were 40 menand 28 women.The treatment for diabetes consisted of diet alone in 9 patients, oral hypoglycemic agents in 36 patients, and insulin therapy in 23 patients. The control group consisted of 170 healthy adults with no abnormalities on biochemistry tests and urinalysis who underwent routine annual health checks (60 men and 1 10 women aged 26-65 years;
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Methods
Randomurine samples were collected to determine the urinary PSP level. In diabetic patients, urinary albumin, NAG, apmicroglobulin, and urinary glucose were also measured, as were the creatinine clearance (Ccr), the blood hemoglobin Alc level (HbAlc), the blood 1 ,5-anhydro-D-grucitol (1 ,5AG) level, and the blood PSP level. Urinary PSP, albumin, NAG, and ar microglobulin excretion were all divided by the urinary creatinine level to calculate the respective excretion indices.
Patients wereclassified into a normoalbuminuriagroup (urinary albumin index <20 mg/gCr, n=3 1 ), a microalbuminuria group (urinary albumin index: 20-200 mg/Ccr, n=19), and a macroalbuminuria group (urinary albumin index >200 mg/gCr, n= 1 8) based on the urinary albumin index data. Clinical profiles in each group are shown in Table 1 . PSP was determined by enzyme immunoassay using a monoclonal antibody (5, 7). Albumin and armicroglobulin were determined by radioimmunoassay, NAG, creatinine, and 1,5-AG by colorimetry, urinary glucose by electrode assay (electrophoresis), and HbAlc by HPLC.
Results were expressed as the mean (mean-SD~mean+SD). 
Results
Urinary PSP in healthy adults and diabetic patients Since there was a large variation in the urinary PSP levels determined in the healthy controls, log conversion of the data was done and the meanand standard deviation were determined to be 168 (79-41 1) jig/gCr (8). The mean and standard deviation of the log-converted urinary PSP data were also determined in the diabetic patients. The urinary PSP index for all diabetic patients was 492 (170-1 ,420) |Hg/gCr, which was clearly higher than that of the healthy individuals (p<0.01). The correlation coefficients for the relation of urinary PSP with urinary glucose, HbAlc, and 1,5-AG were 0.ll, 0.20 and -0.02, respectively, with no significant correlations being observed.
Progression of diabetic nephropathy in relation to urinary albumin and urinary PSP Figure 1 . Urinary PSP index in the healthy controls and diabetic patients classified into three groups. The index was significantly higher than that of the healthy control patients in all groups (*p<0.01). The PSP index of the macroalbuminuria group was also significantly higher than that of the normoalbuminuria group (**p<0.01). C: healthy controls, AU: albuminuria. microalbuminuria, and macroalbuminuria groups, respectively (Fig. 1) . The index was significantly higher than that of the healthy control patients in all groups (p<0.01). The PSP index of the macroalbuminuria group was also significantly higher than that of the normoalbuminuria group (p<0.01). Furthermore, there was a significant correlation between the urinary PSP index and the urinary albumin index (r=0.42, p<0.01, n=68) (Fig. 2) .
Relationship
between urinary PSP and urinary NAG, ocr microglobulin, blood PSP level or Ccr There was a significant correlation between the urinary PSP and NAGindices in the diabetic patients (r=0.35, p<0.01 , n=68) (Fig. 3) . The urinary PSP and armicroglobulin indices also showed a significant correlation (r=0.68, p<0.01 , n-68) (Fig. 4) . There wasa significant negative correlation betweenthe urinary PSP index and Ccr (r=0.39, p<0.01, n=68) (Fig. 5) . There was also a significant negative correlation between the blood PSP concentration and the Ccr (r=-0.52, p<0.01 , n=68) (Fig. 6) . Urinary NAG index (U/g of creatinine) Figure 3 . There was a significant correlation between the urinary PSP and NAG indices in the diabetic patients.
Discussion
Wehave previously reported that urinary PSP excretion is increased in patients with renal disease (6, 8). In the present study, wealso confirmed an increase of urinary PSP excretion w ith the progression of diabetic nephropathy. Two mechanisms have been suggested to explain the increase of urinary PSP excretion in diabetic nephropathy.
PSP is mainly synthesized in the pancreas and is secreted into the pancreaticjuice. However, as with various pancreatic enzymes, it can also be found circulating in the blood (7). Since PSP is a low molecular weight protein of 14-19 kd, it crosses the glomerular basement membrane and undergoes reabsorption in Wepreviously observed that some patients with renal dis- Creatinine clearance (ml/min) Figure 6 . There was also a significant negative correlation between the blood PSP concentration and the Ccr.
ease had urinary PSP with a form different from that found in their blood.
These data suggest that PSP is also synthesized in the kidneys and released into the urine following renal damage (6). In the present study, the mechanism underlying the urinary excretion of PSP was investigated based on the correlations with armicroglobulin and NAG excretion. A significant correlation was found between urinary PSP excretion and both ocr microglobulin and NAG excretion, with the correlation being stronger for the former. In addition, since a correlation was also observed between Ccr and the blood PSP level, it seems probable that PSP accumulates in the urine like a ! -microglobulin. Therefore, as with a!-microglobulin, the increase in urinary PSP excretion is more likely to reflect renal tubular dysfunction rather than release from damaged renal tubules. In addition to In the present study, the progression of nephropathy in our diabetic patients was therefore assessed from the urinary albumin excretion.
When urinary PSP excretion was investigated, it was significantly higher than that of healthy controls not only in the microalbuminuria and macroalbuminuria groups, but also in the normoalbuminuria group. However, other factors must be investigated to confirm whether or not this increase in urinary PSP excretion indicates the initial stage of diabetic nephropathy.
Although urinary PSP excretion increases in pancreatic disease and various serious illnesses which require intensive care (6), none of the subjects in the present study had pancreatic disease and none of them had any severe acute illnesses. Furthermore, since there was no correlation between urinary PSP and urinary glucose, HbAlc, or 1,5-AG it is unlikely that hyperglycemia itself influenced urinary PSP excretion. Therefore, the increase of urinary PSP excretion in the normoalbuminuria group suggests that there is damage to the kidneys, including the renal tubules, even at this early stage. On the other hand, analysis of the macroalbuminuria group showed that there were also cases where PSP excretion did not increase despite severe nephropathy. These results suggest the heterogenecity of diabetic nephropathy. To study the characteristics of the heterogenecity of the nephropathy using various urinary proteins may contribute to the classification of pathogenesis, prognosis and development of prevention in diabetic nephropathy. Further research (including histopathological studies) must be conducted to determine the mechanisms involved.
